Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Lung Cancer

  Free Subscription


Articles published in BMC Cancer

Retrieve available abstracts of 124 articles:
HTML format
Text format



Single Articles


    July 2017
  1. FUGAZZARO S, Costi S, Mainini C, Kopliku B, et al
    PUREAIR protocol: randomized controlled trial of intensive pulmonary rehabilitation versus standard care in patients undergoing surgical resection for lung cancer.
    BMC Cancer. 2017;17:508.
    PubMed     Text format     Abstract available


  2. KIM EY, Jung JY, Kim A, Kim K, et al
    Methionyl-tRNA synthetase overexpression is associated with poor clinical outcomes in non-small cell lung cancer.
    BMC Cancer. 2017;17:467.
    PubMed     Text format     Abstract available


  3. ZHOU Q, Song Y, Zhang X, Chen GY, et al
    A multicenter survey of first-line treatment patterns and gene aberration test status of patients with unresectable Stage IIIB/IV nonsquamous non-small cell lung cancer in China (CTONG 1506).
    BMC Cancer. 2017;17:462.
    PubMed     Text format     Abstract available


    May 2017
  4. MISUMI Y, Okamoto H, Sasaki J, Masuda N, et al
    Phase I/II study of induction chemotherapy using carboplatin plus irinotecan and sequential thoracic radiotherapy (TRT) for elderly patients with limited-disease small-cell lung cancer (LD-SCLC): TORG 0604.
    BMC Cancer. 2017;17:377.
    PubMed     Text format     Abstract available


  5. YEO J, Crawford EL, Zhang X, Khuder S, et al
    A lung cancer risk classifier comprising genome maintenance genes measured in normal bronchial epithelial cells.
    BMC Cancer. 2017;17:301.
    PubMed     Text format     Abstract available


  6. NAKAMURA K, Kato M, Shukuya T, Mori K, et al
    Surfactant protein-D predicts prognosis of interstitial lung disease induced by anticancer agents in advanced lung cancer: a case control study.
    BMC Cancer. 2017;17:302.
    PubMed     Text format     Abstract available


    April 2017
  7. ZHOU T, Zhan J, Fang W, Zhao Y, et al
    Serum low-density lipoprotein and low-density lipoprotein expression level at diagnosis are favorable prognostic factors in patients with small-cell lung cancer (SCLC).
    BMC Cancer. 2017;17:269.
    PubMed     Text format     Abstract available


  8. ZHAO F, Zhou Y, Ge PF, Huang CJ, et al
    A prediction model for lymph node metastases using pathologic features in patients intraoperatively diagnosed as stage I non-small cell lung cancer.
    BMC Cancer. 2017;17:267.
    PubMed     Text format     Abstract available


  9. HORIMASU Y, Ishikawa N, Tanaka S, Hirano C, et al
    MUC1 in lung adenocarcinoma: cross-sectional genetic and serological study.
    BMC Cancer. 2017;17:263.
    PubMed     Text format     Abstract available


  10. LI MX, He H, Ruan ZH, Zhu YX, et al
    Central nervous system progression in advanced non-small cell lung cancer patients with EGFR mutations in response to first-line treatment with two EGFR-TKIs, gefitinib and erlotinib: a comparative study.
    BMC Cancer. 2017;17:245.
    PubMed     Text format     Abstract available


    March 2017
  11. FRUGTNIET BA, Martin TA, Zhang L, Jiang WG, et al
    Neural Wiskott-Aldrich syndrome protein (nWASP) is implicated in human lung cancer invasion.
    BMC Cancer. 2017;17:224.
    PubMed     Text format     Abstract available


  12. SULLIVAN FM, Farmer E, Mair FS, Treweek S, et al
    Detection in blood of autoantibodies to tumour antigens as a case-finding method in lung cancer using the EarlyCDT(R)-Lung Test (ECLS): study protocol for a randomized controlled trial.
    BMC Cancer. 2017;17:187.
    PubMed     Text format     Abstract available


  13. WANG JZ, Xiang JJ, Wu LG, Bai YS, et al
    A genetic variant in long non-coding RNA MALAT1 associated with survival outcome among patients with advanced lung adenocarcinoma: a survival cohort analysis.
    BMC Cancer. 2017;17:167.
    PubMed     Text format     Abstract available


    February 2017
  14. DERMAN BA, Macklis JN, Azeem MS, Sayidine S, et al
    Relationships between longitudinal neutrophil to lymphocyte ratios, body weight changes, and overall survival in patients with non-small cell lung cancer.
    BMC Cancer. 2017;17:141.
    PubMed     Text format     Abstract available


  15. SHI L, Xu Z, Wu G, Chen X, et al
    Up-regulation of miR-146a increases the sensitivity of non-small cell lung cancer to DDP by downregulating cyclin J.
    BMC Cancer. 2017;17:138.
    PubMed     Text format     Abstract available


  16. LIN C, Majoor CJ, Roelofs JJ, de Kruif MD, et al
    Potential importance of protease activated receptor (PAR)-1 expression in the tumor stroma of non-small-cell lung cancer.
    BMC Cancer. 2017;17:113.
    PubMed     Text format     Abstract available


  17. ZHANG L, Liu D, Li L, Pu D, et al
    The important role of circulating CYFRA21-1 in metastasis diagnosis and prognostic value compared with carcinoembryonic antigen and neuron-specific enolase in lung cancer patients.
    BMC Cancer. 2017;17:96.
    PubMed     Text format     Abstract available


    January 2017
  18. DENG X, Zheng Z, Lin B, Su H, et al
    The efficacy and roles of combining temozolomide with whole brain radiotherapy in protection neurocognitive function and improvement quality of life of non-small-cell lung cancer patients with brain metastases.
    BMC Cancer. 2017;17:42.
    PubMed     Text format     Abstract available


    November 2016
  19. HALD SM, Kiselev Y, Al-Saad S, Richardsen E, et al
    Erratum to: Prognostic impact of CXCL16 and CXCR6 in non-small cell lung cancer: combined high CXCL16 expression in tumor stroma and cancer cells yields improved survival.
    BMC Cancer. 2016;16:916.
    PubMed     Text format    


  20. RAPP J, Kiss E, Meggyes M, Szabo-Meleg E, et al
    Increased Wnt5a in squamous cell lung carcinoma inhibits endothelial cell motility.
    BMC Cancer. 2016;16:915.
    PubMed     Text format     Abstract available


  21. SU S, Hu Y, Ouyang W, Ma Z, et al
    Might radiation therapy in addition to chemotherapy improve overall survival of patients with non-oligometastatic Stage IV non-small cell lung cancer?: Secondary analysis of two prospective studies.
    BMC Cancer. 2016;16:908.
    PubMed     Text format     Abstract available


  22. ZHOU L, Yu L, Zhu B, Wu S, et al
    Metastasis-associated in colon cancer-1 and aldehyde dehydrogenase 1 are metastatic and prognostic biomarker for non-small cell lung cancer.
    BMC Cancer. 2016;16:876.
    PubMed     Text format     Abstract available


  23. KO R, Kenmotsu H, Serizawa M, Koh Y, et al
    Frequency of EGFR T790M mutation and multimutational profiles of rebiopsy samples from non-small cell lung cancer developing acquired resistance to EGFR tyrosine kinase inhibitors in Japanese patients.
    BMC Cancer. 2016;16:864.
    PubMed     Text format     Abstract available


  24. CHEN YM, Lai CH, Rau KM, Huang CH, et al
    Impact of clinical parameters and systemic inflammatory status on epidermal growth factor receptor-mutant non-small cell lung cancer patients readministration with epidermal growth factor receptor tyrosine kinase inhibitors.
    BMC Cancer. 2016;16:868.
    PubMed     Text format     Abstract available


  25. PAN CH, Chang YF, Lee MS, Wen BC, et al
    Vorinostat enhances the cisplatin-mediated anticancer effects in small cell lung cancer cells.
    BMC Cancer. 2016;16:857.
    PubMed     Text format     Abstract available


  26. BIAOXUE R, Hua L, Wenlong G, Shuanying Y, et al
    Increased serum amyloid A as potential diagnostic marker for lung cancer: a meta-analysis based on nine studies.
    BMC Cancer. 2016;16:836.
    PubMed     Text format     Abstract available


    October 2016
  27. HAN JY, Choi JJ, Kim JY, Han YL, et al
    Erratum to: PNA clamping-assisted fluorescence melting curve analysis for detecting EGFR and KRAS mutations in the circulating tumor DNA of patients with advanced non-small cell lung cancer.
    BMC Cancer. 2016;16:803.
    PubMed     Text format    


  28. STANKEVICIUS V, Vasauskas G, Bulotiene D, Butkyte S, et al
    Gene and miRNA expression signature of Lewis lung carcinoma LLC1 cells in extracellular matrix enriched microenvironment.
    BMC Cancer. 2016;16:789.
    PubMed     Text format     Abstract available


  29. WU MF, Jian ZH, Huang JY, Jan CF, et al
    Post-inhaled corticosteroid pulmonary tuberculosis and pneumonia increases lung cancer in patients with COPD.
    BMC Cancer. 2016;16:778.
    PubMed     Text format     Abstract available


    January 2016
  30. KIM EY, Cho EN, Park HS, Kim A, et al
    Genetic heterogeneity of actionable genes between primary and metastatic tumor in lung adenocarcinoma.
    BMC Cancer. 2016;16:27.
    PubMed     Text format     Abstract available


  31. JIANG W, Fan H, Qian C, Ding J, et al
    Prognostic value of high FoxC2 expression in resectable non-small cell lung cancer, alone or in combination with E-cadherin expression.
    BMC Cancer. 2016;16:16.
    PubMed     Text format     Abstract available


  32. SAMULIN ERDEM J, Skaug V, Bakke P, Gulsvik A, et al
    Mutations in TP53 increase the risk of SOX2 copy number alterations and silencing of TP53 reduces SOX2 expression in non-small cell lung cancer.
    BMC Cancer. 2016;16:28.
    PubMed     Text format     Abstract available


  33. KHAN P, Manna A, Saha S, Mohanty S, et al
    Aspirin inhibits epithelial-to-mesenchymal transition and migration of oncogenic K-ras-expressing non-small cell lung carcinoma cells by down-regulating E-cadherin repressor Slug.
    BMC Cancer. 2016;16:39.
    PubMed     Text format     Abstract available


  34. SLAVOVA-AZMANOVA NS, Lizama C, Johnson CE, Ludewick HP, et al
    Impact of the introduction of EBUS on time to management decision, complications, and invasive modalities used to diagnose and stage lung cancer: a pragmatic pre-post study.
    BMC Cancer. 2016;16:44.
    PubMed     Text format     Abstract available


  35. CASADEI GARDINI A, Mariotti M, Lucchesi A, Pini S, et al
    Paraneoplastic lipase and amylase production in a patient with small-cell lung cancer: case report.
    BMC Cancer. 2016;16:118.
    PubMed     Text format     Abstract available


  36. TIECHE CC, Peng RW, Dorn P, Froment L, et al
    Prolonged pemetrexed pretreatment augments persistence of cisplatin-induced DNA damage and eliminates resistant lung cancer stem-like cells associated with EMT.
    BMC Cancer. 2016;16:125.
    PubMed     Text format     Abstract available


  37. FITENI F, Anota A, Westeel V, Bonnetain F, et al
    Methodology of health-related quality of life analysis in phase III advanced non-small-cell lung cancer clinical trials: a critical review.
    BMC Cancer. 2016;16:122.
    PubMed     Text format     Abstract available


  38. ZHANG SY, Hui LP, Li CY, Gao J, et al
    More expression of BDNF associates with lung squamous cell carcinoma and is critical to the proliferation and invasion of lung cancer cells.
    BMC Cancer. 2016;16:171.
    PubMed     Text format     Abstract available


  39. NIU FY, Zhou Q, Yang JJ, Zhong WZ, et al
    Distribution and prognosis of uncommon metastases from non-small cell lung cancer.
    BMC Cancer. 2016;16:149.
    PubMed     Text format     Abstract available


  40. LEE VH, Leung DK, Choy TS, Lam KO, et al
    Efficacy and safety of afatinib in Chinese patients with EGFR-mutated metastatic non-small-cell lung cancer (NSCLC) previously responsive to first-generation tyrosine-kinase inhibitors (TKI) and chemotherapy: comparison with historical cohort using er
    BMC Cancer. 2016;16:147.
    PubMed     Text format     Abstract available


  41. ALAM MM, Sohoni S, Kalainayakan SP, Garrossian M, et al
    Cyclopamine tartrate, an inhibitor of Hedgehog signaling, strongly interferes with mitochondrial function and suppresses aerobic respiration in lung cancer cells.
    BMC Cancer. 2016;16:150.
    PubMed     Text format     Abstract available


  42. KATO M, Shukuya T, Mori K, Kanemaru R, et al
    Cerebral infarction in advanced non-small cell lung cancer: a case control study.
    BMC Cancer. 2016;16:203.
    PubMed     Text format     Abstract available


  43. FUKUI T, Itabashi M, Ishihara M, Hiyoshi Y, et al
    Prognostic factors affecting the risk of thoracic progression in extensive-stage small cell lung cancer.
    BMC Cancer. 2016;16:197.
    PubMed     Text format     Abstract available


  44. PINEDA AL, Ogoe HA, Balasubramanian JB, Rangel Escareno C, et al
    On Predicting lung cancer subtypes using 'omic' data from tumor and tumor-adjacent histologically-normal tissue.
    BMC Cancer. 2016;16:184.
    PubMed     Text format     Abstract available


  45. CHO A, Hur J, Moon YW, Hong SR, et al
    Correlation between EGFR gene mutation, cytologic tumor markers, 18F-FDG uptake in non-small cell lung cancer.
    BMC Cancer. 2016;16:224.
    PubMed     Text format     Abstract available


  46. MANAPOV F, Niyazi M, Gerum S, Roengvoraphoj O, et al
    Evaluation of the role of remission status in a heterogeneous limited disease small-cell lung cancer patient cohort treated with definitive chemoradiotherapy.
    BMC Cancer. 2016;16:216.
    PubMed     Text format     Abstract available


  47. QUERE G, Descourt R, Robinet G, Autret S, et al
    Mutational status of synchronous and metachronous tumor samples in patients with metastatic non-small-cell lung cancer.
    BMC Cancer. 2016;16:210.
    PubMed     Text format     Abstract available


  48. NOGUCHI-SASAKI M, Sasaki Y, Shimonaka Y, Mori K, et al
    Treatment with anti-IL-6 receptor antibody prevented increase in serum hepcidin levels and improved anemia in mice inoculated with IL-6-producing lung carcinoma cells.
    BMC Cancer. 2016;16:270.
    PubMed     Text format     Abstract available


  49. SUN XJ, Deng QH, Yu XM, Ji YL, et al
    A phase II study of Endostatin in combination with paclitaxel, carboplatin, and radiotherapy in patients with unresectable locally advanced non-small cell lung cancer.
    BMC Cancer. 2016;16:266.
    PubMed     Text format     Abstract available


  50. SUN Y, Cheng Y, Hao X, Wang J, et al
    Randomized phase III trial of amrubicin/cisplatin versus etoposide/cisplatin as first-line treatment for extensive small-cell lung cancer.
    BMC Cancer. 2016;16:265.
    PubMed     Text format     Abstract available


  51. QUAIFE SL, Ruparel M, Beeken RJ, McEwen A, et al
    The Lung Screen Uptake Trial (LSUT): protocol for a randomised controlled demonstration lung cancer screening pilot testing a targeted invitation strategy for high risk and 'hard-to-reach' patients.
    BMC Cancer. 2016;16:281.
    PubMed     Text format     Abstract available


  52. ELHARRAR X, Barbolosi D, Ciccolini J, Meille C, et al
    A phase Ia/Ib clinical trial of metronomic chemotherapy based on a mathematical model of oral vinorelbine in metastatic non-small cell lung cancer and malignant pleural mesothelioma: rationale and study protocol.
    BMC Cancer. 2016;16:278.
    PubMed     Text format     Abstract available


  53. DUAN L, Hu X, Jin Y, Liu R, et al
    Survivin protein expression is involved in the progression of non-small cell lung cancer in Asians: a meta-analysis.
    BMC Cancer. 2016;16:276.
    PubMed     Text format     Abstract available


  54. GIBBERD A, Supramaniam R, Dillon A, Armstrong BK, et al
    Lung cancer treatment and mortality for Aboriginal people in New South Wales, Australia: results from a population-based record linkage study and medical record audit.
    BMC Cancer. 2016;16:289.
    PubMed     Text format     Abstract available


  55. REN XC, Wang QY, Zhang R, Chen XJ, et al
    Accelerated hypofractionated three-dimensional conformal radiation therapy (3 Gy/fraction) combined with concurrent chemotherapy for patients with unresectable stage III non-small cell lung cancer: preliminary results of an early terminated phase II t
    BMC Cancer. 2016;16:288.
    PubMed     Text format     Abstract available


  56. LI X, Lin F, Zhou H
    Genetic polymorphism rs3760396 of the chemokine (C-C motif) ligand 2 gene (CCL2) associated with the susceptibility of lung cancer in a pathological subtype-specific manner in Han-ancestry Chinese: a case control study.
    BMC Cancer. 2016;16:298.
    PubMed     Text format     Abstract available


  57. KOZUKI T, Nogami N, Kitajima H, Iwasawa S, et al
    Feasibility study of first-line chemotherapy using Pemetrexed and Bevacizumab for advanced or recurrent nonsquamous non-small cell lung cancer in elderly patients: TORG1015.
    BMC Cancer. 2016;16:306.
    PubMed     Text format     Abstract available


  58. ZHANG Y, Xu X, Zhang M, Wang X, et al
    MicroRNA-663a is downregulated in non-small cell lung cancer and inhibits proliferation and invasion by targeting JunD.
    BMC Cancer. 2016;16:315.
    PubMed     Text format     Abstract available


  59. BONANNO L, Costa C, Majem M, Sanchez JJ, et al
    Combinatory effect of BRCA1 and HERC2 expression on outcome in advanced non-small-cell lung cancer.
    BMC Cancer. 2016;16:312.
    PubMed     Text format     Abstract available


  60. COLOMBARA DV, Manhart LE, Carter JJ, Hawes SE, et al
    Absence of an association of human polyomavirus and papillomavirus infection with lung cancer in China: a nested case-control study.
    BMC Cancer. 2016;16:342.
    PubMed     Text format     Abstract available


  61. TOMINAGA T, Tsuchiya T, Mochinaga K, Arai J, et al
    Epidermal growth factor signals regulate dihydropyrimidine dehydrogenase expression in EGFR-mutated non-small-cell lung cancer.
    BMC Cancer. 2016;16:354.
    PubMed     Text format     Abstract available


  62. FLECKENSTEIN J, Petroff A, Schafers HJ, Wehler T, et al
    Long-term outcomes in radically treated synchronous vs. metachronous oligometastatic non-small-cell lung cancer.
    BMC Cancer. 2016;16:348.
    PubMed     Text format     Abstract available


  63. TUFMAN A, Huber RM, Volk S, Aigner F, et al
    Interleukin-22 is elevated in lavage from patients with lung cancer and other pulmonary diseases.
    BMC Cancer. 2016;16:409.
    PubMed     Text format     Abstract available


  64. BEHRENS T, Gross I, Siemiatycki J, Conway DI, et al
    Occupational prestige, social mobility and the association with lung cancer in men.
    BMC Cancer. 2016;16:395.
    PubMed     Text format     Abstract available


  65. CASADEI GARDINI A, Chiadini E, Faloppi L, Marisi G, et al
    Efficacy of sorafenib in BRAF-mutated non-small-cell lung cancer (NSCLC) and no response in synchronous BRAF wild type-hepatocellular carcinoma: a case report.
    BMC Cancer. 2016;16:429.
    PubMed     Text format     Abstract available


  66. PARK S, Kim HJ, Choi CM, Lee DH, et al
    Predictive factors for a long-term response duration in non-squamous cell lung cancer patients treated with pemetrexed.
    BMC Cancer. 2016;16:417.
    PubMed     Text format     Abstract available


  67. SRIPLUNG H, Yeesoonsang S, McNeil E, Bilheem S, et al
    The use of a multiple imputation method to investigate the trends in Histologic types of lung cancer in Songkhla province, Thailand, 1989-2013.
    BMC Cancer. 2016;16:389.
    PubMed     Text format     Abstract available


  68. RENO TA, Tong SW, Wu J, Fidler JM, et al
    The triptolide derivative MRx102 inhibits Wnt pathway activation and has potent anti-tumor effects in lung cancer.
    BMC Cancer. 2016;16:439.
    PubMed     Text format     Abstract available


  69. ZHAO R, Zhou S, Xia B, Zhang CY, et al
    AT-101 enhances gefitinib sensitivity in non-small cell lung cancer with EGFR T790M mutations.
    BMC Cancer. 2016;16:491.
    PubMed     Text format     Abstract available


  70. WISKEMANN J, Hummler S, Diepold C, Keil M, et al
    POSITIVE study: physical exercise program in non-operable lung cancer patients undergoing palliative treatment.
    BMC Cancer. 2016;16:499.
    PubMed     Text format     Abstract available


  71. ROUANNE M, Adam J, Goubar A, Robin A, et al
    Osteopontin and thrombospondin-1 play opposite roles in promoting tumor aggressiveness of primary resected non-small cell lung cancer.
    BMC Cancer. 2016;16:483.
    PubMed     Text format     Abstract available


  72. HAN K, Claret L, Sandler A, Das A, et al
    Modeling and simulation of maintenance treatment in first-line non-small cell lung cancer with external validation.
    BMC Cancer. 2016;16:473.
    PubMed     Text format     Abstract available


  73. GAO J, Meng Q, Zhao Y, Chen X, et al
    EHD1 confers resistance to cisplatin in non-small cell lung cancer by regulating intracellular cisplatin concentrations.
    BMC Cancer. 2016;16:470.
    PubMed     Text format     Abstract available


  74. FUKUSHI S, Yoshino H, Yoshizawa A, Kashiwakura I, et al
    p53-independent structure-activity relationships of 3-ring mesogenic compounds' activity as cytotoxic effects against human non-small cell lung cancer lines.
    BMC Cancer. 2016;16:521.
    PubMed     Text format     Abstract available


  75. YUN YH, Kim YA, Sim JA, Shin AS, et al
    Prognostic value of quality of life score in disease-free survivors of surgically-treated lung cancer.
    BMC Cancer. 2016;16:505.
    PubMed     Text format     Abstract available


  76. WU J, Lin Y, He X, Yang H, et al
    Comparison of detection methods and follow-up study on the tyrosine kinase inhibitors therapy in non-small cell lung cancer patients with ROS1 fusion rearrangement.
    BMC Cancer. 2016;16:599.
    PubMed     Text format     Abstract available


  77. LIN PC, Huang HD, Chang CC, Chang YS, et al
    Long noncoding RNA TUG1 is downregulated in non-small cell lung cancer and can regulate CELF1 on binding to PRC2.
    BMC Cancer. 2016;16:583.
    PubMed     Text format     Abstract available


  78. KITAO T, Hirata K, Shima K, Hayashi T, et al
    Reproducibility and uptake time dependency of volume-based parameters on FDG-PET for lung cancer.
    BMC Cancer. 2016;16:576.
    PubMed     Text format     Abstract available


  79. CHO C, Horzempa C, Jones D, McKeown-Longo PJ, et al
    The fibronectin III-1 domain activates a PI3-Kinase/Akt signaling pathway leading to alphavbeta5 integrin activation and TRAIL resistance in human lung cancer cells.
    BMC Cancer. 2016;16:574.
    PubMed     Text format     Abstract available


  80. WON B, Mambetsariev I, Salgia R
    Post-crizotinib management of effective ceritinib therapy in a patient with ALK-positive non-small cell lung cancer.
    BMC Cancer. 2016;16:568.
    PubMed     Text format     Abstract available


  81. SHENG X, Wang Z
    Protein arginine methyltransferase 5 regulates multiple signaling pathways to promote lung cancer cell proliferation.
    BMC Cancer. 2016;16:567.
    PubMed     Text format     Abstract available


  82. MATTSSON JS, Brunnstrom H, Jabs V, Edlund K, et al
    Inconsistent results in the analysis of ALK rearrangements in non-small cell lung cancer.
    BMC Cancer. 2016;16:603.
    PubMed     Text format     Abstract available


  83. HAN JY, Choi JJ, Kim JY, Han YL, et al
    PNA clamping-assisted fluorescence melting curve analysis for detecting EGFR and KRAS mutations in the circulating tumor DNA of patients with advanced non-small cell lung cancer.
    BMC Cancer. 2016;16:627.
    PubMed     Text format     Abstract available


  84. ARRIETA O, Varela-Santoyo E, Soto-Perez-de-Celis E, Sanchez-Reyes R, et al
    Metformin use and its effect on survival in diabetic patients with advanced non-small cell lung cancer.
    BMC Cancer. 2016;16:633.
    PubMed     Text format     Abstract available


  85. YUE T, Zheng X, Dou Y, Zheng X, et al
    Interleukin 12 shows a better curative effect on lung cancer than paclitaxel and cisplatin doublet chemotherapy.
    BMC Cancer. 2016;16:665.
    PubMed     Text format     Abstract available


  86. NIIBE Y, Nishimura T, Inoue T, Karasawa K, et al
    Oligo-recurrence predicts favorable prognosis of brain-only oligometastases in patients with non-small cell lung cancer treated with stereotactic radiosurgery or stereotactic radiotherapy: a multi-institutional study of 61 subjects.
    BMC Cancer. 2016;16:659.
    PubMed     Text format     Abstract available


  87. OH IJ, Kim KS, Park CK, Kim YC, et al
    Belotecan/cisplatin versus etoposide/cisplatin in previously untreated patients with extensive-stage small cell lung carcinoma: a multi-center randomized phase III trial.
    BMC Cancer. 2016;16:690.
    PubMed     Text format     Abstract available


  88. CATHCART MC, Useckaite Z, Drakeford C, Semik V, et al
    Anti-cancer effects of baicalein in non-small cell lung cancer in-vitro and in-vivo.
    BMC Cancer. 2016;16:707.
    PubMed     Text format     Abstract available


  89. KIM HS, Heo JS, Lee J, Lee JY, et al
    The impact of KRAS mutations on prognosis in surgically resected colorectal cancer patients with liver and lung metastases: a retrospective analysis.
    BMC Cancer. 2016;16:120.
    PubMed     Text format     Abstract available


    May 2015
  90. LEPORATI P, Fonte R, de Martinis L, Zambelli A, et al
    A male patient with acromegaly and breast cancer: treating acromegaly to control tumor progression.
    BMC Cancer. 2015;15:397.
    PubMed     Text format     Abstract available


    April 2015
  91. GILLGRASS AE, Chew MV, Krneta T, Ashkar AA, et al
    Overexpression of IL-15 promotes tumor destruction via NK1.1+ cells in a spontaneous breast cancer model.
    BMC Cancer. 2015;15:293.
    PubMed     Text format     Abstract available


    January 2015
  92. CHAO A, Lai CH, Lee YS, Ueng SH, et al
    Molecular characteristics of endometrial cancer coexisting with peritoneal malignant mesothelioma in Li-Fraumeni-like syndrome.
    BMC Cancer. 2015;15:8.
    PubMed     Text format     Abstract available


  93. KUMAR V, Becker K, Zheng HX, Huang Y, et al
    The performance of NLST screening criteria in Asian lung cancer patients.
    BMC Cancer. 2015;15:916.
    PubMed     Text format     Abstract available


  94. MC MENAMIN UC, Cardwell CR, Hughes CM, Murray LM, et al
    Low-dose aspirin and survival from lung cancer: a population-based cohort study.
    BMC Cancer. 2015;15:911.
    PubMed     Text format     Abstract available


  95. GULDBRANDT LM, Fenger-Gron M, Rasmussen TR, Rasmussen F, et al
    The effect of direct access to CT scan in early lung cancer detection: an unblinded, cluster-randomised trial.
    BMC Cancer. 2015;15:934.
    PubMed     Text format     Abstract available


  96. GREVE G, Schiffmann I, Pfeifer D, Pantic M, et al
    The pan-HDAC inhibitor panobinostat acts as a sensitizer for erlotinib activity in EGFR-mutated and -wildtype non-small cell lung cancer cells.
    BMC Cancer. 2015;15:947.
    PubMed     Text format     Abstract available


  97. YANG XQ, Li CY, Xu MF, Zhao H, et al
    Comparison of first-line chemotherapy based on irinotecan or other drugs to treat non-small cell lung cancer in stage IIIB/IV: a systematic review and meta-analysis.
    BMC Cancer. 2015;15:949.
    PubMed     Text format     Abstract available


  98. HOPMANS W, Damman OC, Senan S, Hartemink KJ, et al
    A patient perspective on shared decision making in stage I non-small cell lung cancer: a mixed methods study.
    BMC Cancer. 2015;15:959.
    PubMed     Text format     Abstract available


  99. CHIU CC, Chou HL, Chen BH, Chang KF, et al
    BPIQ, a novel synthetic quinoline derivative, inhibits growth and induces mitochondrial apoptosis of lung cancer cells in vitro and in zebrafish xenograft model.
    BMC Cancer. 2015;15:962.
    PubMed     Text format     Abstract available


  100. MAZZONE PJ, Wang XF, Lim S, Choi H, et al
    Accuracy of volatile urine biomarkers for the detection and characterization of lung cancer.
    BMC Cancer. 2015;15:1001.
    PubMed     Text format     Abstract available


  101. IMAI H, Kaira K, Mori K, Ono A, et al
    Prognostic significance of diabetes mellitus in locally advanced non-small cell lung cancer.
    BMC Cancer. 2015;15:989.
    PubMed     Text format     Abstract available


  102. SAFI S, Beckhove P, Warth A, Benner A, et al
    A randomized phase II study of radiation induced immune boost in operable non-small cell lung cancer (RadImmune trial).
    BMC Cancer. 2015;15:988.
    PubMed     Text format     Abstract available


  103. VASHI PG, Edwin P, Popiel B, Gupta D, et al
    The relationship between circulating 25-hydroxyvitamin D and survival in newly diagnosed advanced non-small-cell lung cancer.
    BMC Cancer. 2015;15:1012.
    PubMed     Text format     Abstract available


  104. ZANG G, Gustafsson K, Jamalpour M, Hong J, et al
    Vascular dysfunction and increased metastasis of B16F10 melanomas in Shb deficient mice as compared with their wild type counterparts.
    BMC Cancer. 2015;15:234.
    PubMed     Text format     Abstract available


  105. COLLAUD S, Tischler V, Atanassoff A, Wiedl T, et al
    Lung neuroendocrine tumors: correlation of ubiquitinylation and sumoylation with nucleo-cytosolic partitioning of PTEN.
    BMC Cancer. 2015;15:74.
    PubMed     Text format     Abstract available


  106. KITADA M, Ohsaki Y, Matsuda Y, Hayashi S, et al
    Photodynamic diagnosis of pleural malignant lesions with a combination of 5-aminolevulinic acid and intrinsic fluorescence observation systems.
    BMC Cancer. 2015;15:174.
    PubMed     Text format     Abstract available


  107. YEH HH, Tseng YF, Hsu YC, Lan SH, et al
    Ras induces experimental lung metastasis through up-regulation of RbAp46 to suppress RECK promoter activity.
    BMC Cancer. 2015;15:172.
    PubMed     Text format     Abstract available


  108. NORMANNO N, Cree IA
    Genomics driven-oncology: challenges and perspectives.
    BMC Cancer. 2015;15:141.
    PubMed     Text format     Abstract available


  109. KERSHAW S, Cummings J, Morris K, Tugwood J, et al
    Optimisation of immunofluorescence methods to determine MCT1 and MCT4 expression in circulating tumour cells.
    BMC Cancer. 2015;15:387.
    PubMed     Text format     Abstract available


  110. KALRA N, Zhang J, Thomas A, Xi L, et al
    Mesothelioma patient derived tumor xenografts with defined BAP1 mutations that mimic the molecular characteristics of human malignant mesothelioma.
    BMC Cancer. 2015;15:376.
    PubMed     Text format     Abstract available


  111. NORO R, Seike M, Zou F, Soeno C, et al
    MET FISH-positive status predicts short progression-free survival and overall survival after gefitinib treatment in lung adenocarcinoma with EGFR mutation.
    BMC Cancer. 2015;15:31.
    PubMed     Text format     Abstract available


  112. TAKAYOSHI K, Sagara K, Uchino K, Kusaba H, et al
    A case of metastatic renal cell carcinoma and bile duct carcinoma treated with a combination of sunitinib and gemcitabine.
    BMC Cancer. 2015;15:426.
    PubMed     Text format     Abstract available


  113. SEMENISTY V, Naroditsky I, Keidar Z, Bar-Sela G, et al
    Pazopanib for metastatic pulmonary epithelioid hemangioendothelioma-a suitable treatment option: case report and review of anti-angiogenic treatment options.
    BMC Cancer. 2015;15:402.
    PubMed     Text format     Abstract available


  114. ROBL B, Pauli C, Botter SM, Bode-Lesniewska B, et al
    Prognostic value of tumor suppressors in osteosarcoma before and after neoadjuvant chemotherapy.
    BMC Cancer. 2015;15:379.
    PubMed     Text format     Abstract available


  115. EIDE HA, Halvorsen AR, Bjaanaes MM, Piri H, et al
    The MYCN-HMGA2-CDKN2A pathway in non-small cell lung carcinoma-differences in histological subtypes.
    BMC Cancer. 2016;16:71.
    PubMed     Text format     Abstract available


  116. YUAN Y, Wang W, Li H, Yu Y, et al
    Nonsense and missense mutation of mitochondrial ND6 gene promotes cell migration and invasion in human lung adenocarcinoma.
    BMC Cancer. 2015;15:346.
    PubMed     Text format     Abstract available


  117. GAVINE PR, Wang M, Yu D, Hu E, et al
    Identification and validation of dysregulated MAPK7 (ERK5) as a novel oncogenic target in squamous cell lung and esophageal carcinoma.
    BMC Cancer. 2015;15:454.
    PubMed     Text format     Abstract available


  118. HO AL, Szulakowsi P, Mohamid WH
    The diagnostic challenge of pulmonary tumour thrombotic microangiopathy as a presentation for metastatic gastric cancer: a case report and review of the literature.
    BMC Cancer. 2015;15:450.
    PubMed     Text format     Abstract available


  119. LIANG H, Fu Z, Jiang X, Wang N, et al
    miR-16 promotes the apoptosis of human cancer cells by targeting FEAT.
    BMC Cancer. 2015;15:448.
    PubMed     Text format     Abstract available


  120. LIU L, Yu H, Huang X, Tan H, et al
    A novel engineered VEGF blocker with an excellent pharmacokinetic profile and robust anti-tumor activity.
    BMC Cancer. 2015;15:170.
    PubMed     Text format     Abstract available


  121. KRAMER MG, Masner M, Casales E, Moreno M, et al
    Neoadjuvant administration of Semliki Forest virus expressing interleukin-12 combined with attenuated Salmonella eradicates breast cancer metastasis and achieves long-term survival in immunocompetent mice.
    BMC Cancer. 2015;15:620.
    PubMed     Text format     Abstract available


  122. PAIVA TF JR, de Jesus VH, Marques RA, da Costa AA, et al
    Angiogenesis-related protein expression in bevacizumab-treated metastatic colorectal cancer: NOTCH1 detrimental to overall survival.
    BMC Cancer. 2015;15:643.
    PubMed     Text format     Abstract available


  123. PEI S, Yang X, Wang H, Zhang H, et al
    Plantamajoside, a potential anti-tumor herbal medicine inhibits breast cancer growth and pulmonary metastasis by decreasing the activity of matrix metalloproteinase-9 and -2.
    BMC Cancer. 2015;15:965.
    PubMed     Text format     Abstract available


  124. LEE SJ, Kang WY, Yoon Y, Jin JY, et al
    Natural killer (NK) cells inhibit systemic metastasis of glioblastoma cells and have therapeutic effects against glioblastomas in the brain.
    BMC Cancer. 2015;15:1011.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: